Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24475342 | 0.95 | HRH3 (0.34) | VCPCYP1A2CYP2D6HRH3MGLL | |
| SCHEMBL24475337 | 0.81 | MGLL (0.33) | HRH3ACHEMGLL | |
| SCHEMBL21794544 | 0.78 | VCP (0.43) | VCPCYP2D6HRH3NCF1ACHE | |
| SCHEMBL24475619 | 0.77 | VCP (0.39) | VCPCYP1A2CYP2D6HRH3NCF1 | |
| SCHEMBL22520757 | 0.77 | VCP (0.41) | VCPCYP1A2CYP2D6HRH3 | |
| SCHEMBL24475330 | 0.76 | HRH3 (0.36) | VCPCYP1A2CYP2D6HRH3NCF1 | |
| SCHEMBL13741206 | 0.75 | HRH3 (0.45) | VCPCYP1A2CYP2D6HRH3 | |
| SCHEMBL22520686 | 0.74 | MGLL (0.31) | HRH3MGLL | |
| SCHEMBL14768674 | 0.72 | MGLL (0.36) | CYP2D6MGLL | |
| SCHEMBL6448305 | 0.71 | NCF1 (0.43) | CYP1A2CYP2D6HRH3NCF1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | VCP 659/4885CYP1A2 467/4885CYP2D6 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.